Please login to the form below

Not currently logged in
Email:
Password:

RNAi

This page shows the latest RNAi news and features for those working in and with pharma, biotech and healthcare.

Arbutus hit hard as new hep B drug fails on safety

Arbutus hit hard as new hep B drug fails on safety

It has since abandoned the programme in favour of follow-up RNAi drug AB-729, while another candidate – RNA destabiliser AB-452 – has been delayed by safety concerns.

Latest news

More from news
Approximately 7 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Dicerna/. Lilly. GalXC RNAi technology platform for targets in Cardiometabolic disease, neurodegeneration and pain.

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    This has been Alnylam’s story over the past 16 years, as it built on Andrew Fire and Craig Mello’s Nobel prize winning discovery that naturally occurring RNAi “silences” genes, ... Its RNAi technology can be used to target any gene expressed in

  • Boosting pharma’s metabolic rate Boosting pharma’s metabolic rate

    New frontiers such as cell therapy and RNAi are becoming therapeutic realities and exciting new challenges are coming over the horizon, creating a constantly shifting landscape that leaders must navigate.

  • Deal Watch September 2016 Deal Watch September 2016

    800. Arrowhead / Amgen. Licences. 2 agreements to develop and commercialise RNAi therapies in CVS disease, upfront payments of $35m, $21.5m in equity plus $617m in option payments. ... 95. Geron / J&J. Licence. Exclusive worldwide rights to Geron's

  • Pharma deals during January 2014 Pharma deals during January 2014

    The deal comprised a range of RNAi assets including pre-clinical candidates, IP and delivery technologies. ... The other deal announced by Alnylam was the expansion of its deal with Sanofi (Genzyme unit_ to develop RNAi therapeutics in rare diseases.

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Bruce Peacock joins Dicerna from Ophthotech Bruce Peacock joins Dicerna from Ophthotech

    Massachusetts-headquartered Dicerna develops RNAi-based therapeutics with a focus on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

  • Silence appoints chief medical officer Silence appoints chief medical officer

    These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • How do you define a biotech company?

    This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where 

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...
Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...

Infographics